Press Releases Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 09/03/2026 GMT			5-day change	1st Jan Change
0.2000 ^USD	-6.76%		-9.21%	-42.16%

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI

Press Releases

12-04	Virax Biolabs : Announces Closing of $5 Million Private Placement	PU
12-04	Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement	PR
12-03	Virax Biolabs : Announces $5 Million Private Placement	PU
12-03	Virax Biolabs Group Limited Announces $5 Million Private Placement	PR
12-03	Virax Biolabs' : CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PU
12-03	Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PR
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	PR
27/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025 FINAL V2)	PU
10/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025)	PU
26/08/25	Virax Biolabs : Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberV	PU
26/08/25	Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September	PR
08/08/25	Virax Biolabs : Major New Study Reveals Immunological Insights Into ME/CFS, Further Supporting Blood-based Diagnostic Testing and Research	PU
29/07/25	Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy	PR
18/07/25	Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency	PR
09/07/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck July 2025)	PU
18/12/24	Virax Biolabs CEO James Foster Issues Letter to Shareholders	AQ
17/12/24	Virax Biolabs' : CEO James Foster Issues Letter to Shareholders Form 6 K	PU
11/12/24	Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland	AQ
10/12/24	Virax Biolabs : Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland Form 6 K	PU
20/11/24	Virax Biolabs : Unaudited Condensed Consolidated Interim Financial Statements as of September 30, 2024 Form 6 K	PU
31/10/24	Virax Biolabs : Notice of 2024 Annual General Meeting of Shareholders To Be Held on Form 6 K	PU
24/10/24	Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland	AQ
24/10/24	Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX	AQ
23/10/24	Virax Biolabs : Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland Form 6 K	PU
30/09/24	Virax Biolabs : Market Offering Agreement Form 6 K	PU